An Eight-Week, Randomized, Double-Blind, Parallel-Group, Pilot Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg in Comparison With Valsartan 320 mg in Patients With Mild to Moderate Hypertension During Exercise After a Missed Dose.
Latest Information Update: 03 Apr 2012
At a glance
- Drugs Aliskiren (Primary) ; Valsartan
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Novartis
Most Recent Events
- 20 Jun 2011 Results presented at the 21st European Meeting on Hypertension.
- 29 Oct 2009 Actual patient number (68) added as reported by ClinicalTrials.gov.
- 29 Oct 2009 Actual end date (October 2009) added as reported by ClinicalTrials.gov.